Professor Steve Gensler was appointed OU Athletics FAR in September 2024. He joined the faculty of the College of Law in 2000. He is the Edwards Family Chair in Law, and holds a David L. Boren ...

CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...

Workers at Butterfly Effect, an artificial-intelligence startup with Chinese roots, gathered in March to count down to the launch of a demo of a new AI-powered tool called Manus. Released in the ...

Prof. Booth is Professor of Engineering Science at the University of Oxford. His research involves the development and application of adaptive optical methods in microscopy, laser-based materials ...

FLATIRON DISTRICT, Manhattan (WABC) -- As a college math professor, Steve Warner knows a thing or two about crunching numbers. After he purchased his apartment in 2022, however, Warner met a problem ...

After over a month of government shutdown, NASA finally released new images of mysterious interstellar object 3I/ATLAS on Wednesday. During the livestreamed event, NASA brass took pains to “address ...

The recent release of thousands of emails that late sex offender Jeffrey Epstein exchanged with associates has renewed interest in the disgraced financier’s connection to star Harvard University ...

Harvard Psychology professor Steven A. Pinker condemned the rise of cancel culture in higher education at an Institute of Politics forum on Wednesday, telling his audience that academics must avoid ...

Harvard psychology professor Steven Pinker said there was a "grain of truth" to President Donald Trump's argument that Harvard University was a "liberal mess." "President Trump has described Harvard ...

For generations, federal research funding to universities has fueled breakthroughs in medicine, technology, and national defense. Now, the White House is using that support as leverage — pressuring a ...

The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...